Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.

Journal: Eye (London, England)
PMID: 35523860

Abstract

OBJECTIVES: To assess the therapeutic response to brolucizumab and aflibercept by deep learning/OCT-based analysis of macular fluid volumes in neovascular age-related macular degeneration.

Authors

  • Ursula Schmidt-Erfurth
    Christian Doppler Laboratory for Ophthalmic Image Analysis (OPTIMA), Department of Ophthalmology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.
  • Zufar Mulyukov
    Novartis Pharma AG, Basel, Switzerland.
  • Bianca S Gerendas
    Christian Doppler Laboratory for Ophthalmic Image Analysis (OPTIMA), Department of Ophthalmology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.
  • Gregor S Reiter
    Department of Ophthalmology and Optometry, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. gregor.reiter@meduniwien.ac.at.
  • Daniel Lorand
    Novartis Pharma AG, Basel, Switzerland.
  • Georges Weissgerber
    Novartis Pharma AG, Basel, Switzerland.
  • Hrvoje Bogunović
    Christian Doppler Laboratory for Ophthalmic Image Analysis (OPTIMA), Department of Ophthalmology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.

Keywords

External Resources

Popular Topics
Recent Journals